(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 April 2003 (10.04.2003)

PCT

(10) International Publication Number
WO 03/028722 A1

(51) International Patent Classification[7]: A61K 31/42, 31/20 // (A61K 39/42, 31:70)

(21) International Application Number: PCT/IL01/00927

(22) International Filing Date: 4 October 2001 (04.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant *(for all designated States except US)*: **XTL BIOPHARMACEUTICALS LTD** [IL/IL]; Kiryat Weizmann, P.O. Box 370, 76100 Rehovot (IL).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DAGAN, Shlomo** [IL/IL]; Lotus 5, 74037 Nes-Ziona (IL). **EREN, Rachel** [IL/IL]; Shikun Banim 121, 76870 Netaim (IL).

(74) Agent: **LOTAN, Mirit**; XTL Biopharmaceuticals Ltd., Kiryat Weizmann, P.O. Box 370, 76100 Rehovot (IL).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** TREATMENT OF HEPATITIS B VIRUS INFECTION WITH HUMAN MONOCLONAL ANTIBODIES



(57) **Abstract:** Disclosed is a pharmaceutical composition for the treatment or prevention of hepatitis B virus infection, comprising a 1:3 mixture of two fully human anti HBsAg monoclonal antibodies 19.79 and 17.1.41. Alto disclosed are preferred modes of administration. The pharmaceutical composition can be given as a monotherapy or in combination with other anti viral agents.

WO 03/028722 A1